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Abstract 
Background: Primary hyperaparathyroidism (pHPT) is often accompanied by underlying 
thyroid pathology that can confound preoperative parathyroid localization studies and com-
plicate intra-operative decision making. The aim of this study was to examine the utility of 
preoperative thyroid ultrasonography (US) in patients prior to undergoing parathyroidec-
tomy for pHPT. 
Methods: An Institutional Review Board approved prospective study was undertaken from 
January 2005 through July 2008. All patients with pHPT meeting inclusion criteria (n=94) 
underwent preoperative thyroid ultrasound in addition to standard 
99mTc-sestamibi scintig-
raphy for parathyroid localization. Demographics, operative management and final pathology 
were examined in all cases. 
Results: Fifty-four of the 94 patients (57%) were noted to have a thyroid nodule on pre-
operative US, of which 30 (56%) underwent further examination with fine needle aspiration 
biopsy. Alteration of the operative plan attributable to underlying thyroid pathology occurred 
in 16 patients (17%), with patients undergoing either total thyroidectomy (n=9) or thyroid 
lobectomy (n=7). Thyroid cancer was noted in 33% of patients undergoing thyroid resection, 
and 6% of all patients with HPT.  
Conclusions: The routine utilization of preoperative thyroid ultrasound in patients prior to 
undergoing parathyroid surgery for pHPT is indicated. The added information from  this 
non-invasive modality facilitates timely management of co-incidental, and sometimes malig-
nant, thyroid pathology. 
Key words: hyperparathyroidism, thyroid, ultrasound, surgery, thyroid cancer. 
Introduction 
Primary  hyperparathyroidism  (pHPT)  is  a 
common endocrine disorder with an incidence of 0.4 
to 1 per 1,000 individuals, with a peak during the 5 th 
and 6  th decades of life.  1 Symptomatic patients, and 
those without symptoms that meet the guidelines for 
the  2002  NIH  Consensus  Development  Panel  for 
Ivyspring  
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asymptomatic pHPT, are candidates for parathyroid 
surgery.  2  The  incidence  of  thyroid  cancer  has  pro-
gressively increased in the United States over the past 
decade. The treatment of thyroid carcinoma is surgi-
cal, and requires thyroid lobectomy / isthmusectomy, 
total thyroidectomy, or total thyroidectomy with cen-
tral  lymph  node  dissection  (ATA  Guidelines  2009), 
depending  upon  stage  of  disease.  3  Concomitant 
pHPT in the setting of thyroid disease can present a 
surgical challenge for  surgeons caring for these pa-
tients.  Since  Ogburn  first  described  synchronous 
primary hyperparathyroidism and thyroid carcinoma 
more than fifty years ago, there have been multiple 
reports examining these co-existing endocrine disor-
ders.  4  Rates  of  co-existing  primary  hyperparathy-
roidism  and  thyroid  pathology  range  from  20-67%, 
with  synchronous  thyroid  cancer  occurring  in  2  to 
24%. 4,5,6,7,8,9  
The standard surgical management of primary 
hyperparathyroidism has been bilateral neck explora-
tion. This allowed the surgeon to examine all 4 para-
thyroid glands, but also allowed for a thorough ex-
amination of the thyroid gland. This approach often 
resulted  in  the  identification  and  resection  of  con-
comitant  thyroid  disease.  However,  the  modern 
management  of  primary  hyperparathyroidism  has 
moved  towards  minimally  invasive  approaches 
guided by nuclear medicine localization studies (99m 
Tc-sestamibi  scintigraphy)  and  intra-operative  para-
thyroid  hormone  (PTH)  testing.  This  surgical  ap-
proach  allows  for  small  incisions,  lower  morbidity, 
but  less  exposure  of  the  thyroid  gland,  leading  to 
concerns  about  missing  co-existent,  and  significant 
thyroid pathology. We undertook a prospective, sin-
gle-arm study examining all patients undergoing an 
operation  for  pHPT  to  determine  the  prevalence  of 
concomitant thyroid disease detected by preoperative 
thyroid ultrasound.  
Material and Methods  
Specific  Aim:  To  determine  the  prevalence  of 
concomitant thyroid disease detected by preoperative 
thyroid ultrasound in patients undergoing surgery for 
pHPT.  
Primary endpoint: The primary outcome varia-
ble in this study was prevalence of co-existent benign 
and malignant thyroid pathology.  
Study  population:  Ninety-four  of  110  patients 
screened  for  eligibility  were  enrolled  in  this  study, 
conducted at two medical centers (Walter Reed Army 
Medical Center from January 2005 through June 2008; 
Johns Hopkins University Hospital from January 2008 
through June 2008) under Institutional Review Board 
approval at the respective institutions and adherence 
to HIPAA compliance. Adult patients, age 18 years 
and older, with pHPT based upon standard diagnos-
tic laboratory criteria, were eligible for inclusion. Pa-
tients  unable  to  provide  informed  consent,  those 
having previously undergone prior thyroid or para-
thyroid surgery, or those with known thyroid disease, 
patients  with  medullary  thyroid  carcinoma  and/or 
multiple  endocrine  neoplasm  syndrome,  and  those 
declining enrollment were excluded.  
Study Design: This was a prospective observa-
tional cohort trial. All study patients initially under-
went both laboratory screening and  99m Tc-sestamibi 
scintigraphy.  Operative  planning  was  developed 
based on clinical findings and the results of the scin-
tigraphy.  Prior  to  surgical  intervention,  thyroid  ul-
trasonography was performed and suspicious thyroid 
findings  were  further  investigated  with  fine  needle 
aspiration  biopsy  (FNAB) and/or  thyroid  resection. 
Any changes in the planned surgical procedure based 
on  thyroid  ultrasonography  findings  and/or  FNA 
results were recorded.  
Statistical  Analysis:  Descriptive  statistics  were 
used  and  study  sample  means  are  presented  with 
standard deviations (mean ± SD).  
Results  
Clinical characteristics and Preoperative Eval-
uation: There were 110 patients evaluated and 94 pa-
tients enrolled: 71 females and 23 males, with a mean 
age of 56±13 years (Table 1). Three patients reported a 
prior history of neck radiation, and a family history of 
thyroid cancer was identified in one patient who had 
a  multi-nodular  goiter  (MNG).  Preoperative  labora-
tory evaluation confirmed hypercalcemia (mean: 11.0 
±  0.5  mg/dl),  elevated  serum  parathyroid  hormone 
levels  (mean:  117.9  ±  50.7  pg/ml)  and  elevated 
24-hour  urine  calcium  (mean:  367.5  ±  180.3  mg/24 
hours) (Table 1). Each patient underwent preopera-
tive  99m  Tc-sestamibi  scintigraphy.  Sestamibi  identi-
fied parathyroid abnormalities in 86% (n=81) of pa-
tients  suggesting  a  single  parathyroid  adenoma  in 
79% (n=74) and double parathyroid adenomas in 8% 
(n=7).  The  remaining  patients  (n=13,  14%)  had  a 
non-localizing  study,  and  underwent  standard  four 
gland exploration.  
Preoperative  Thyroid  Ultrasound:  Ultrasound 
examination revealed co-existent thyroid abnormali-
ties  in  57%  (n=54).  The  abnormalities  ranged  from 
dominant  nodules  <1  cm  in  11  patients,  dominant 
nodules ≥1 cm in 33 patients, and diffuse nodularity 
in  the  remaining  10  patients.  Patients  with  thyroid 
pathology were slightly older (median age 60 versus 
52)  and  more  often  female  (M:F  ratio  1:3.5  versus 
1:2.6)(p=ns).  The  median  size  thyroid  module  size  Journal of Cancer 2012, 3 
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was 1.3 cm for all patients with thyroid pathology, 
and 1.5 cm for those patients that underwent FNAB 
(n=31). Thyroid FNAB results included 3 indetermi-
nate, 25 benign and 3 malignant/suspicious for ma-
lignancy (Table 2).  
Operative Management: Alteration of the oper-
ative plan attributable to underlying thyroid pathol-
ogy occurred in 17% (n=16) of patients. Of these 16 
patients,  in  addition  to  a  parathyroidectomy,  nine 
underwent total thyroidectomy (10%), and seven un-
derwent  thyroid  lobectomy/isthmusectomy  (6%) 
(Figure 1).  
Pathological  Assessment:  Evaluation  of  all  re-
sected parathyroid tissue confirmed that 96% (n=90) 
of  patients  had  a  solitary  adenoma,  2%  (n=2)  had 
double adenomas, 1% (n=1) had 4-gland hyperplasia, 
and 1% had a parathyroid carcinoma (n=1). Among 
the 16 patients who underwent either thyroid lobec-
tomy/isthmusectomy  (n=7)  or  total  thyroidectomy 
(n=9),  5  patients  (31%)  had  papillary  thyroid  carci-
noma (PTC), 1 (6%) patient had follicular thyroid car-
cinoma, 9 (55%) had benign disease (MNG, follicular 
adenoma, Hurthle cell adenoma, adenomatoid nod-
ule), and 1 (6%) had an intra-thyroidal parathyroid 
adenoma  (Figure  1).  The  prevalence  of  occult 
well-differentiated  thyroid  carcinoma  in  this  study 
was  6%  (6/94).  There  was  no  significant  difference 
noted between patients with benign thyroid pathol-
ogy and those with thyroid cancer in regards to pa-
tient age or size of lesion.  
 
 
 
 
 
Figure 1: Evaluation of patients with pHPT by thyroid ultrasound and subsequent management based upon results.  
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Table 1: Patient demographics with pre-operative labor-
atory and radiographic results. 
Demographics  Patients (n=94) 
 Age; Mean  SD (years)  56.1 ± 13.2 
 Gender (Female: Male)   3.1 : 1 
 Race (Caucasian: African American: Other)  12.5 : 2 : 1 
 Prior neck radiation  3 
 Family history of thyroid cancer  2 
Pre-Op Lab Test (n)  Mean  SD 
 Serum Calcium, mg/dl  11.0 ± 0.5 
 PTH, pg/ml  117.9 ± 50.7 
 Urine Calcium, mg/24hrs  367.5 ± 180.3 (n=44) 
99m-Technetium Sestamibi Results  Patients (n=94) 
 Localized parathyroid abnormality  81 (86%) 
 Non-localized   13 (14%) 
 
Table 2: Preoperative thyroid ultrasound results and re-
sultant modifications in operative approach/procedure. 
Preoperative Thyroid Ultrasound Results  Patients (n=94) 
Thyroid Abnormalities Noted  54 (57%) 
Suspicious Nodules  31 (33%) 
Median Nodule Size  1.3 cm 
Fine Needle Aspirations Performed   Patients (n=31) 
Pathology   
 Indeterminate  3 (9.7%) 
 Benign  25 (80.6%) 
 Malignant; suspicious for malignancy  3 (9.7%) 
Planned Operation (Pre-ultrasound)  Patients (n=94) 
 Minimally Invasive Parathyroidectomy  87 (92.5%) 
 Bilateral neck exploration  7 (7.5%) 
Planned Operation (Post-Ultrasound)  Patients (n=94) 
 Minimally Invasive Parathyroidectomy  72 (77%) 
 Bilateral neck exploration  22 (23%) 
Change in Operation (Addition of Thyroid 
Surgery) 
Patients (n=16) 
 Total Thyroidectomy  9 
 Thyroid Lobectomy / Isthmusectomy  7 
 
 
Discussion  
This  study  was  undertaken  to  determine  the 
prevalence of concomitant thyroid disease identified 
by  preoperative  thyroid  US  in  patients  undergoing 
surgical treatment for pHPT. It was also designed to 
determine how often incidentally discovered thyroid 
pathology  would  alter  the  surgical  management  of 
these patients. Additionally, it provided the incidence 
of  non-medullary  thyroid  cancer  in  patients  under-
going surgical management of pHPT.  
Modern  surgical  management  of  pHPT  has 
transitioned from the traditional bilateral neck explo-
ration  to  minimally  invasive  parathyroidectomy 
(MIP). This minimally invasive surgical approach has 
allowed  for  outpatient  surgical  treatment  of  pHPT. 
The lack of preoperative thyroid imaging, however, 
can lead to missed and/or incompletely treated thy-
roid abnormalities. Previous studies have noted that 
in the performance of neck explorations, thyroid le-
sions <1 cm in size are missed 94% of the time, and 
lesions that are 1-2 cm in size are missed 50% of the 
time.  10  Milas  and  colleagues  retrospectively  exam-
ined 1,200 patients with pHPT who underwent bilat-
eral  neck  exploration;  850  patients  did  not  receive 
preoperative  imaging  and  350  patients  underwent 
preoperative  neck  ultrasound  revealing  coexisting 
thyroid  disease  in  43%.  11  The  lack  of  preoperative 
ultrasound led to a 30% thyroid resection rate while 
preoperative ultrasound resulted in 20% of patients 
undergoing FNAB and only 6% undergoing thyroid 
resection. In this current study, over 55% of patients 
with pHPT had thyroid abnormalities with 17% un-
dergoing a thyroid resection. Identification of thyroid 
pathology  leads  to  fewer  thyroid  resections.  Often 
times, isolated thyroid nodules that have benign cy-
tology  on  FNA  can  be  safely  followed  with  serial 
thyroid US thus avoiding the morbidity that can be 
associated with thyroidectomy, specifically recurrent 
laryngeal or superior laryngeal nerve injuries.  
Historically, the prevalence of thyroid cancer in 
patients with pHPT ranged from 1 to 36%.  8,12,13,14,15 
More recent published studies report the coexistence 
of non-medullary thyroid cancer in 2-18% of patients 
operated on for pHPT.  5,8,16,17,18 Strichartz and Giuli-
ano conducted a retrospective review of 308 patients 
who underwent an operation for hyperparathyroid-
ism.  8 Fifty-two (17%) patients had grossly apparent 
thyroid  abnormalities  with  histologically  proven 
thyroid disease, and 11 (4%) had differentiated thy-
roid cancer. Recently, in a retrospective review of 200 
patients with pHPT, Morita, et al., noted that 51% of 
patients with pHPT had concomitant thyroid nodules 
and an overall 6% thyroid malignancy rate. 5 Adler, et 
al.,  noted  similar  results  with  ultrasound  detected 
thyroid abnormalities in 29% of patients with primary 
hyperaparathyroidism, although only 2% of patients 
were ultimately diagnosed with malignancy. 19 In the 
94 patients examined in this prospective study, it was 
noted that over 55% had coexistent thyroid pathology 
noted on preoperative thyroid US, which contributed 
to a change in surgical approach in 17%. More im-
portantly,  6%  of  patients  underwent  successful  and 
timely treatment of well-differentiated thyroid cancer 
that may have otherwise been missed, presented at a 
more  advanced  stage,  and/or  required  re-operative 
neck surgery. Although some might argue that occult  Journal of Cancer 2012, 3 
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well-differentiated  thyroid  cancer  is  of  little  clinical 
concern, is it important to note that the patients with 
occult well-differentiated thyroid cancer (<1 cm) have 
similar nodal and distant metastasis rates to patients 
with larger tumors (>1 cm). 20 Patients with identifia-
ble thyroid abnormalities require diligent clinical in-
vestigation.  Timely  intervention  for  thyroid  cancer 
avoids  not  only  the  risk  and  expense  of  neck 
re-exploration at a later time when the malignancy is 
clinically apparent but also the possibly more locally 
advanced  disease  when  operation  is  delayed.  Early 
diagnosis and timely treatment of thyroid cancer also 
avoids the medico-legal implications for a missed or 
delayed diagnosis.  
Another concern of a missed or delayed diagno-
sis of a thyroid malignancy coincident with pHPT that 
should  be  noted  is  the  requirement  of  re-operative 
surgery and the attendant risk of functionally limiting 
surgical morbidity. Although rates nerve injury rates 
of ~1% are often quoted for thyroid and parathyroid 
resections,  reoperative  thyroid  surgery  has  notable 
increases in morbidity rates with laryngeal nerve in-
jury rates of 1-12% and hypocalcemia in 0.3-15% of 
patients.  21,22,23,24,25,26  Thyroid  surgery  following  pre-
vious parathyroid surgery is clearly not the optimal 
surgical situation. The combined operative manage-
ment  of  simultaneous  thyroid  and  parathyroid  dis-
ease is preferred given its demonstrated safety, as it 
avoids the increased operative morbidity of a second 
neck exploration. 14,15,16 This is particularly important 
in  patients  with  unanticipated  thyroid  malignancy 
who can be treated safely at the time of initial opera-
tion for pHPT.  
This study reinforces what has previously been 
demonstrated  in  patients  with  pHPT;  concomitant 
thyroid disease is not an infrequent occurrence. Pre-
operative thyroid ultrasound in patients with pHPT is 
useful adjunct to parathyroid scintigraphy and iden-
tifying  concurrent  thyroid  disease.  It  has  also  been 
shown  to  be  a  cost-effective  undertaking  when  uti-
lized in conjunction with MIPS. 13 With these points in 
mind,  the  debate  about  the  nature  and  extent  of 
treatment for isolated well-differentiated thyroid car-
cinoma is entertained in an entirely different context 
when considered in combination with pHPT requir-
ing surgical treatment. In line with national endocrine 
disease treatment center practice patterns, our adop-
tion  of  MIPS  for  pHPT  attributable  to  a  localizing 
adenoma precludes exploration of the entire neck and 
careful examination of the thyroid gland at time of 
operation. As such, timely diagnosis and treatment of 
the  frequently  encountered  co-existing  thyroid  dis-
ease as shown in this study is advantageous, particu-
larly considering the increased morbidity associated 
with  a  second  neck  exploration.  Regardless  of  the 
surgical  approach  utilized,  the  inability  to  exclude 
coexistent thyroid pathology strictly on the basis of 
absence  of  palpable  thyroid  abnormality  on  clinical 
examination makes preoperative imaging of the thy-
roid gland with or without selective FNAB of detected 
thyroid  abnormalities  prior  to  parathyroidectomy 
justified. 6,16,27,28  
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